Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: BulbaMan who wrote (14866)	12/22/2004 9:35:48 PM
From: Archie Meeties	Respond to of 52153

Bulba, "my fear is major problems with the drugs will show up before long" That's the purpose of a randomized, controlled trial. If mortality was going to be adversely affected by a drug, the large trials the statins have been subjected to would demonstrate it. Phrased differently, the hurdle to demonstrate differences in mortality is a high one. It is so high that it is extremely unlikely that positive results are due to chance. Therefore, there would have to be some major flaws in the design of the study in order for such results to be reversed through subsequent data. It would require the collective blindness of many researchers and clinicians for such huge flaws to persist unnoticed.